 Bonjour to all. So I propose we get started. So let me introduce myself. I will have the honor to be the sessions of today, Chairman. So my name is Patrick Johnson. Actually, I don't come from academia. I come from the industry. So that would be, let's say, a different angle of approach for synthetic biology and molecular and cell biotech. I work in a software company. And we have been, of course, investing a lot in computational biology. And now we are moving forward to synthetic biology. And so I will host the two sessions this morning and this afternoon. This morning is more dedicated to plant biotech and synthetic biology in the plant arena, I'd say. And this afternoon, although we had to change a short minute the agenda with François, I would say it's more oriented toward technology, platforms, and maybe a little bit of computational approaches for synthetic arena. So what I propose, because plant is not at all my arena to kick the day, I propose just a couple of slides to provide you with a perspective from the industry, from the software industry for synthetic biology, just to give you a context. And of course, since we are in IHAS, also the math that actually the industry companies are working on towards synthetic biology. So just a couple of slides. I won't be long. I was told by François it's 15 minutes. So by 40 minutes and 59, you can throw tomatoes and we can kick to the next session with them. Is it a plant? Yeah, yeah, plant. Exactly. So actually, of course, when we talk about synthetic biology, we talk about engineering, living systems, and complex biosystems. And of course, in my company and in other fields in software arena, people are coming from, I would say, the more classical engineering field where it's, of course, a bottom-up approach, where people are designing parts, then assembling them, then testing them, simulating them, and ultimately producing them. And this is what we have been doing for the past 30 years in my company. So pure engineering work, pure systems engineering field, engineering sciences, which at first glance doesn't seem to have one dime in coming with what we want to do in synthetic biology. At first glance, I said, of course. At second glance, of course, there are a lot of questions that could be arisen in terms of modularity, standardization, emergence, emergence of phenomenon. And of course, in terms of industrial pipelines and production pipelines, a lot of industries, not only pharmaceutical, actually, but a lot of industries, CPG, agrochemical, the green, the white, biotechs, are right now actually leading the way and asking companies like mine to provide tools, industrial tools, to assist them in synthetic biology, in systems biology and in synthetic biology. And so this is what we have been doing. I would, of course, not show you things that actually you guys know more than we do. But right now, let's say the in silico approach is ramping up in the industry. Pharmaceutical is actually lagging behind when we look at energy field, for example, or even agrochemical. And from the industrial pool, the demand is not at all coming from pharmaceutical. If you look at the organizations within industries like the synergies of the world, the phases of the world, the branches of the world, of course, there are some departments for in silico approaches, and they have been for quite some time now. But if you look to exons or to energy players, for example, or even, of course, agrochemical, those guys are more advanced in actually launching programs in the field, public-private partnership, to generate tools that would be scalable and industrial. And so starting with genomics, of course, and of course, linking them with a more classical computational biology that the sector was using. So the slide that I'm showing you is what we have been developing in my company. And it's more, I would say, from the design and engineering space. But the production space has not been tackled so far in the industry at least. If you look to, again, the synergies of the world or even the energy sector, those guys are using right now in silico tools to do modeling, protein engineering, let's say, at least. But when it comes to production pipeline, bioprocesses, manufacturing, chemical manufacturing, and of course, genetic engineering and production, it's very shy to say the least. And my company, for example, who has been investing already one billion on the system's biology side, is now looking for a mature mathematical tool and technological platform to link that with production platforms for bioproduction. So we have been working in systems biology. And of course, when I come back to the Boeing example that you saw on the first slide, already design principles are starting to be modified or changed when we zoom into living systems or modified, modified systems. I have to say that systems biology today, at least in the life science sector, is almost nonexistent from an industrial standpoint. And so for the synthetic biology and bioproduction approaches, it's even worse. So all the marvelous presentation that we are discussing today, I would be, of course, and my company and all the other players in the software arena are watching that with a lot of focus because there is the pool, but there is no practices, no standardization, methodologies. And of course, when it comes to ramping up in the industrial field, it's inevitable that we have to come up with something that is more standardized. Of course, when it comes to mathematical technologies and, let's say, tools and frameworks for systems biology, of course, in my company and in other communities, we have been trying to understand the emerging field. So you see on that kind of slide different approaches not complete, of course. When it comes to trying to understand the behavioral and dynamic of complex systems, the emergence of complex systems, the multi-entities complexity. So there's a lot of mathematical, let's say, frameworks being proposed today, some of which are more coming from the computer science arena, some of which are more coming from the classical engineering computer science electrical field. It's a mess, to be honest. From an industrial standpoint, it's a mess. And it's not complete here. And pretty much what we are observing is that every time you look at one specific case in synthetic biology or systems biology, when it comes to FASH, when it comes to a specific organism that we want to tackle, you have a different formalism being proposed by the academy or a different mathematical framework. There is no overarching underlying layer, at least from our understanding. And of course, this is a demand from my sector to try to see whether there is a more generic or a more agnostic layer to be able to handle the complexity of all the different, for example, hosting platforms that could be used within the industry. So the reason why I'm showing you this is, of course, there are the experiments that are being done in synthetic biology. But the demand, at least from our customers, is also to have some sort of election of a unified framework for modeling, simulation, analysis, and production. And today, it's very fragmented. It's very fragmented. Now, if you look at other industries that have been trying to do modeling, simulation, and production, more in the classical product engineering space, this was the case 25 years ago. It was the same situation 25 years ago. If I take an example, in 1980, in the computer-edited design industry, so it's more engineering sciences, you have 600 companies existing on the field doing modeling, design, analysis, simulation, and production, the so-called CAD, CAM, CAE market, and all of which were specialized on specific use cases or specific families of products. It all has converged and being unified in today, let's say, two or three actors that are trying to unify that on the end-to-end platform. If you look at systems biology and synthetic biology today, guess what? The market today is around 400 and 500 companies. Everyone providing a specific language, or a specific framework, or a specific technological platform, for Algoa, for humans, for Homo sapiens, for different kinds, of course, of hosting organism. And we believe in my sector that there will be a convergence path. We believe that there will be when, of course, I am totally unable to say, but at least not only from the modeling perspective and the simulation perspective, but also from the productions perspective. And the reason why synthetic biology, we believe, is actually, let's say, a catalyst to that convergence. Pretty much like manufacturing was a catalyst for the engineering sector, for the CAD and the CAE, classical product design space. It is because by effectively producing, you understand better how it is done and how it could be modeled. So the message here is that the actual realization is also a catalyst. It's a key catalyst for modeling and engineering in the first place. And this is why we want to invest in that sector. So right now, at least in my company, we are trying to gather a number of tools for systems biology, synthetic biology, of course, classical computational biology and systems biology, but not only from the modeling and design perspective, but also from the processes, bioproduction, and manufacturing perspective. And this is why the synthetic sector is inevitable today. So this is what I already said. We've been monitoring a lot. You will see, at least in some of the presentation this afternoon, which are more related to computational, that there are some advances, also coming from, let's say, semantic web approaches. So the transdisciplinarity is not only coming from your field, from the biotech sector. It is also being driven a lot by not only, of course, mathematics and computer science, but also from the semantic and the web technology. And just to question marks from my side, I showed you a couple of mathematical approaches from the systems biology side. There are many from the synthetic biology side. People are providing biobricks framework in terms of grammars, in terms of component tokens, in terms of generative frameworks. I mean, again, there is a zoology of mathematical and computer science framework to do synthetic biology. Also, there is a variety, very wide, of hosting platforms and technology platforms. I don't know if some of you know the, for example, a company named Intruxon, which claims to be the number one in the US of synthetic DNA. And that company, basically, is every two or three months buying a new technological platform to have the widest hosting, let's say, portfolio of organisms, synthetic organism, to be followed very closely. And, of course, there is the social and the community approach for synthesization. And I believe that this afternoon, we'll have some hint on, for example, the, let's say, computational standardization language effort for synthetic biology with a language called Esbol, for example. So, again, my message here is pretty much like for the design side with systems biology. There is, in my mind, a too wide of a variety of offering. Synthetic biology is following the same way. And as an industry guy, of course, I'm asking and starving for unification and more standardization approaches. So that was just, let's say, not too long, I hope, an overview of the computational sector trying to not only tackle, but be part of the discussions in that field. So today's sessions, again, two blocks. This morning, we'll be focusing more on plant organism and synthetic biology. And we'll start with Ann Osborne. And this afternoon, we'll be more focusing, I guess. I'll try to find a unification, because we had some short minute change in the agenda in terms of computational tools and technological platform. And that's all from my side. So I propose to welcome Ann Osborne, who will talk about mechanism of chemical diversification and plants. Thank you.